Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies
2019 · Cancer Cell · 1,057 citations
https://doi.org/10.1016/j.ccell.2019.02.001
D
Ding Ma
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
312
Papers
11.7K
Citations
47
h-index
159
i10-index
Ding Ma is an academic researcher from Hefei University of Technology. The author has contributed to research in topics: Cancer Genomics and Diagnostics & Ovarian cancer diagnosis and treatment & Endometrial and Cervical Cancer Treatments. The author has an h-index of 47, co-authored 266 publications.
ORCID: 0000-0002-4778-7854Papers by this author
worksFerroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy
2022 · Cell Metabolism · 527 citations
https://doi.org/10.1016/j.cmet.2022.09.021
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
2023 · Signal Transduction and Targeted Therapy · 482 citations
https://doi.org/10.1038/s41392-023-01522-4
Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets
2020 · Cell Metabolism · 467 citations
https://doi.org/10.1016/j.cmet.2020.10.012
The human long non-coding RNA-RoR is a p53 repressor in response to DNA damage
2012 · Cell Research · 299 citations
https://doi.org/10.1038/cr.2012.164
Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance
2020 · The Oncologist · 199 citations
https://doi.org/10.1634/theoncologist.2019-0982
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat